This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

31 Jan 2011

J&J Receives Acquisition Approval from European Commission

Johnson & Johnson has received the approval from the European Commission for its proposed acquisition of Crucell, a global biopharmaceutical company.

Johnson & Johnson and Crucell announced on January 28 that the European Commission has granted approval for Johnson & Johnson's proposed acquisition of Crucell, a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies.


Reference is made to the joint press release of Johnson & Johnson and Crucell N.V., dated 8 December 2010 announcing the recommended cash offer by Johnson & Johnson for all of the issued and outstanding ordinary shares in the capital of Crucell N.V. (Crucell), including those represented by American depositary shares,

Related News